Highlights Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Market Closed - Euronext Amsterdam Other stock markets 11:35:08 2024-05-16 am EDT			5-day change	1st Jan Change
0.752 ^EUR	-1.44%		-7.16%	-90.76%

Apr. 24	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
Mar. 15	Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vivoryon Therapeutics N.V. Provides Update on Viviad Phase 2B Study of Varoglutamstat in Early Alzheimer?S Disease	Mar. 04	CI
Vivoryon Therapeutics N.V. Provides Comprehensive Progress Report for Ongoing Varoglutamstat Clinical Program Following R&D Event and VIVA-MIND DSMB Dose Decision	23-10-26	CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2023	23-09-07	CI
Vivoryon Therapeutics N.V. Shares Clinical Development Update Highlighting Progress of N3pE-Amyloid-targeting Small Molecule Varoglutamstat in Alzheimerâ€™s Disease	23-07-16	CI
Vivoryon Rises 7% on EUR25 Million Capital Raise	23-05-26	MT
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Vivoryon Therapeutics N.V. Provides Progress Update on Varoglutamstat Clinical Development for the Treatment of Alzheimer's Disease	23-03-28	CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-30	CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Half Year Ended June 30, 2022	22-09-30	CI
Vivoryon Therapeutics Presents Key Phase 2b Data at AAIC 2022 Showing that Varoglutamstat is Well Tolerated at Doses with High Target Inhibition, Highlighting Unique O (News with Additional Features)	22-07-31	CI
Vivoryon Therapeutics N.V. Reports Positive Independent Data Safety Monitoring Board Recommendation for Phase 2B Study of Varoglutamstat in AD	22-06-23	CI
Vivoryon Therapeutics N.V. Announces the Appointment of Dr. Claudia Riedl and Samir Shah to its Non-Executive Board of Directors	22-06-22	CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Full Year Ended December 31, 2021	22-04-28	CI
Vivoryon Therapeutics Wins China Nod to Start Clinical Trial of Alzheimer's Therapy	22-02-28	MT
Simcere Pharma Wins Clinical Trial Approval in China for Alzheimer's Disease Treatment	22-02-27	MT
Vivoryon Therapeutics N.V. and Simcere Pharmaceutical Group Ltd Announce CDE Approval of Chinese Clinical Trial Application for Varoglutamstat (SIM0408, PQ912) in Patients with Alzheimer's Disease	22-02-27	CI
Vivoryon Therapeutics N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-04	CI
Vivoryon Therapeutics N : Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer’s Disease	21-10-18	PU
Vivoryon Therapeutics N.V.: Vivoryon Therapeutics Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer's Disease	21-10-18	EQ
Vivoryon Therapeutics N.V Provides Update on Business and Progress of Varoglutamstat Clinical Development in Alzheimer's Disease (News with Additional Features)	21-10-18	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Highlights

Filters